Miruvor
Sign up
The short answer

What studies of oxaloacetate found

12papers on oxaloacetate
77people in 2 studies testing oxaloacetate alone
2randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: D Little or no difference

Based on the strongest evidence, the placebo trial (very low certainty): 3 of 5 findings are D.

5 outcomes rated · see each below

ME/CFS: D Little or no difference

Based on the strongest evidence, the placebo trial (very low certainty), for fatigue.

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, studies found little or no difference with oxaloacetate. For ME/CFS, studies found little or no difference with oxaloacetate. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 12 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Oxaloacetate · Long COVID is hereOxaloacetate · ME/CFS is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Cognition (brain fog)1 study · 35 people took oxaloacetate Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (69 in all).

The placebo trial69 randomised · 42 days · 2,000 mg of OAA, two 500 mg capsules with breakfast and two 500 mg capsules with lunch each day

Cognition (brain fog) improved more than in the comparison group.

The evidence is very uncertain about the effect of oxaloacetate on cognition (brain fog) in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (69 in all)
See the 1 study
  1. REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID. (2025)

    People in the study
    69 randomised
    Dose
    2,000 mg of OAA, two 500 mg capsules with breakfast and two 500 mg capsules with lunch each day
    Outcome
    Total Cognitive Efficiency Defense Automated Neurobehavioral Assessment (DANA) Brain Vital
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
Fatigue1 study · 35 people took oxaloacetate Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 69 people found no clear difference; a small benefit can't be ruled out.

The placebo trial69 randomised · 42 days · 2,000 mg of OAA, two 500 mg capsules with breakfast and two 500 mg capsules with lunch each day

No clear difference in fatigue.

The evidence is very uncertain about the effect of oxaloacetate on fatigue in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 69 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID. (2025)

    People in the study
    69 randomised
    Dose
    2,000 mg of OAA, two 500 mg capsules with breakfast and two 500 mg capsules with lunch each day
    Outcome
    Total Chalder score Chalder Fatigue Questionnaire
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Low

Daily life and health overall

Overall symptoms1 study · 35 people took oxaloacetate Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (69 in all).

The placebo trial69 randomised · 42 days · 2,000 mg of OAA, two 500 mg capsules with breakfast and two 500 mg capsules with lunch each day

Overall symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of oxaloacetate on overall symptoms in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (69 in all)
See the 1 study
  1. REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID. (2025)

    People in the study
    69 randomised
    Dose
    2,000 mg of OAA, two 500 mg capsules with breakfast and two 500 mg capsules with lunch each day
    Outcome
    DSQ-SF total symptom burden DePaul Symptom Questionnaire Short Form
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
Daily functioning1 study · 35 people took oxaloacetate Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 69 people found no clear difference; a small benefit can't be ruled out.

The placebo trial69 randomised · 42 days · 2,000 mg of OAA, two 500 mg capsules with breakfast and two 500 mg capsules with lunch each day

No clear difference in daily functioning.

The evidence is very uncertain about the effect of oxaloacetate on daily functioning in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 69 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID. (2025)

    People in the study
    69 randomised
    Dose
    2,000 mg of OAA, two 500 mg capsules with breakfast and two 500 mg capsules with lunch each day
    Outcome
    UP Time upright activity
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
Quality of life1 study · 35 people took oxaloacetate Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 69 people found no clear difference; a small benefit can't be ruled out.

The placebo trial69 randomised · 42 days · 2,000 mg of OAA, two 500 mg capsules with breakfast and two 500 mg capsules with lunch each day

No clear difference in quality of life.

The evidence is very uncertain about the effect of oxaloacetate on quality of life in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 69 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID. (2025)

    People in the study
    69 randomised
    Dose
    2,000 mg of OAA, two 500 mg capsules with breakfast and two 500 mg capsules with lunch each day
    Outcome
    RAND-36 energy domain
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Low

ME/CFS

Fatigue1 study · 42 people took oxaloacetate Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 82 people found no clear difference; a small benefit can't be ruled out.

The placebo trial82 randomised · three-month · 2,000 mg/day, twice daily

No clear difference in fatigue.

The evidence is very uncertain about the effect of oxaloacetate on fatigue in ME/CFS. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 82 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. RESTORE ME: a RCT of oxaloacetate for improving fatigue in patients with myalgic encephalomyelitis/chronic fatigue syndrome. (2024)

    People in the study
    82 randomised
    Dose
    2,000 mg/day, twice daily
    Outcome
    Chalder fatigue score between-group trend at study end Chalder Fatigue Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    High
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    High

Side effects

Stopping because of side effects2 studies
Side effects studies reported6 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Headache3 studies
Nausea or stomach upset2 studies
Dizziness1 study
Fatigue1 study
Trouble sleeping1 study
Worse symptoms or a flare1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    0 mg at the start in most studies

  2. 2Top dose

    Most often 0 mg (3 of 4 studies)

Doses across 4 studies

0 to 0 mg. One study of 76 people went up to 500 mg.

Each study’s dose, as printed

Systematic reviews

Reviews pool earlier studies. Each shows when it was published and how far its search went.

All papers

  1. Relationships between fatigue, cognitive function, and upright activity in a randomized trial of oxaloacetate for myalgic encephalomyelitis/chronic fatigue syndrome.2025 · placebo trial · 82 randomised
    Summary

    In this 90-day randomized, controlled, double blinded clinical trial at the Bateman Horne Center, 82 adults aged 18 to 65 with ME/CFS and self-reported upright activity between 2 and 6 h per day received 2,000 mg/day oxaloacetate (OAA) or a control of 2,000 mg rice flour. There were four in-person visits, on Day 1, 30, 60 and 90. Measures included the Chalder Fatigue Questionnaire, DANA Brain Vital cognitive efficiency, and UP Time from a wearable device. Percent change in DANA cognitive efficiency differed between groups at Visit 3 (p = 0.034), with trends at Visit 2 (p = 0.063) and Visit 4 (p = 0.053). A group-by-fatigue interaction was reported (p = 0.006); in the OAA group higher fatigue was associated with reduced cognitive improvement (β = −0.34, p < 0.0001), while the control group showed no significant relationship (r = 0.03, p = 0.77). Percent change in UP Time differed at Visit 2 (p = 0.044), not at Visits 3 and 4 (p > 0.10). At Visit 4, responder distributions did not differ significantly (χ2 = 6.22, df = 3, p = 0.10). Harms were not reported, and withdrawal counts were not reported.

  2. Dietary Supplementation for Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systematic Review.2025 · systematic review
    Summary

    This systematic review asked whether dietary supplements reduce fatigue in ME/CFS. It included 14 studies (7%) identified from 189 papers searched in Ebsco Host, PubMed, Scopus, and Google Scholar; the final search was 7 May 2024. Supplements varied and included ImmunoVita®, Supradyn®, probiotics, CoQ10 with selenium or NADH, GAA, carnitine, AEO, and acclydine; treatment periods reported in the text included 36 weeks and ten weeks. Comparisons varied across the included studies. Outcomes were mainly self-report fatigue questionnaires plus quality of life, activity, and laboratory markers. Findings were mixed: some supplements were reported to reduce fatigue scores or improve cognitive fatigue, while others showed no significant fatigue changes; AEO was reported to reduce fatigue for 22–33% of participants, ENADA® showed improvement in 31%, and ALC/PLC was followed by worsening symptoms in many patients. Six out of fourteen studies reported adverse effects, including nausea, dyspepsia, insomnia, and others. The authors state no firm conclusions can be drawn due to small sample sizes and missing data, and note limitations such as focusing on fatigue as the only primary outcome.

  3. Nutraceutical Supplementation Effects on Subjective Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review.2025 · systematic review
    Summary

    Review authors searched ClinicalTrials.gov, Medline, PubMed, Cochrane and Web of Science for interventional studies of nutraceuticals or diet in adults with ME/CFS and included 14 studies, described as randomised controlled trials and open-label pilot trials. Interventions included CoQ10 (alone or with alpha-lipoic acid, NADH or selenium), NADH, melatonin with zinc, anhydrous enol-oxaloacetate, sodium dichloroacetate, hydrogen water, Ginkgo with Cistanche, guanidinoacetic acid, 6-methylsulfinylhexyl isothiocyanate, D-ribose, porcine serum polypeptide and probiotics, given for varying durations, with fatigue measured by self-report scales. CoQ10 plus alpha-lipoic acid lowered FSS scores (p < 0.0001); CoQ10 plus NADH lowered FIS-40 (p = 0.03; p < 0.001) and maximum HR (p = 0.022), with pain and sleep not significant; CoQ10 plus selenium lowered FIS-40 (p = 0.021); melatonin with zinc lowered FIS-40 (p < 0.05) without improving sleep or anxiety; probiotics improved the mental component (p = 0.043). Fatigue was not significant with guanidinoacetic acid, or with 6-MSITC on the CFQ-11. Reported side effects included dyspepsia (2/23 at 500 mg BID and 2/24 at 1,000 mg BID) and insomnia (1/26) with enol-oxaloacetate, epigastralgia and dizziness, tremor in one patient, and symptom flare-up in one patient. A meta-analysis was not conducted.

  4. The Post-COVID syndrome caused by excessive inflammation: pathogenesis, potential targets and therapeutic agents.2026 · review
    Summary

    This review examined pharmacological interventions for post-COVID syndrome (PCS) predominantly characterised by persistent fatigue, with no participants of its own. It summarised studies of CoQ10 plus ALA, cacao flavonoids, amantadine, L-arginine plus vitamin C, fluvoxamine, astragalus root extract, Myelophil/MYPplus, Paxlovid, abrocitinib, upadacitinib, AXA1125, oxaloacetate, nicotinamide riboside, fexofenadine plus famotidine and IVIg. In a prospective observational study, 174 people with long COVID were enrolled and 116 received CoQ10 plus ALA; 53.5% had a complete FSS response versus 3.5% in the control group, and the non-response rate was 9.5% versus 25.9%. A cacao flavonoid trial (n = 46) reported improvements after 90 days. An open-label amantadine trial enrolled 83 patients; after 2 weeks scores were significantly superior to control (P < 0.001). A single-blind trial in 46 patients reported fatigue in 8.7% with L-arginine plus vitamin C versus 80.1% with placebo at day 28 (p < 0.0001). A fluvoxamine trial enrolled 399 patients and reduced FSS scores at day 60 and day 90; the fluvoxamine group had a lower incidence of adverse events, with rare serious adverse reactions. An astragalus trial reported chronic fatigue prevalence falling from 100% to 13.8%, and 17.2% one month later, versus 80.0% and 70.0% with placebo (P < 0.0001). A phase IIa AXA1125 trial found no overall differences in objective mitochondrial function between treatment and placebo. Amantadine was well tolerated with no notable safety concerns; astragalus had no obvious adverse reactions. Current evidence is mainly from observational studies or small-sample RCTs and is insufficient as definitive evidence of efficacy.

  5. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): diagnosis and management.2025 · review
    Summary

    This narrative review searched PubMed, Web of Science, Embase, and the Cochrane Library from inception to August 2025 and included 211 publications on ME/CFS diagnosis, pathophysiology, assessment, and treatment. It summarized pharmacological and non-pharmacological interventions. Reported examples include a double-blind, randomized, placebo-controlled trial of IVIG in 99 CFS patients that found an absence of dose-dependent efficacy; a Phase III rintatolimod study in 208 ME/CFS patients in which 51.2% of a severely debilitated subgroup (n = 21/41) had a ≥ 25% improvement in exercise treadmill test duration; a 12-week trial in 207 ME/CFS patients reporting significant reductions in fatigue with CoQ10 (200 mg) and nicotinamide adenine dinucleotide (20 mg); LDN showing significant improvement in 73.9% of 218 ME/CFS patients; and a pilot study of 55 ME/CFS patients in which oral minocycline produced favorable symptom improvements for 80% of treatment completers. A pooled analysis of 1,298 ME/CFS patients from eight trials associated CBT with significant reductions in fatigue severity and functional impairment. A pragmatic trial in 241 adolescents (aged 8–17) found no significant inter-group difference between GET and activity management for physical function on the Short-Form 36 at 6 months. A systematic review and meta-analysis reported a significant reduction in fatigue (Hedges’ g = -0.52) and an improvement in physical function with pacing compared with no treatment or routine care. Harms included GET-associated symptom exacerbation in a significant proportion of patients, and rintatolimod adverse events may occur. TCM findings should be cautiously interpreted because the available evidence is constrained by methodological limitations.

  6. A Comprehensive Scoping Review on Diet and Nutrition in Relation to Long COVID-19 Symptoms and Recovery.2025 · review
    Summary

    This scoping review synthesized 50 studies (27 intervention and 23 observational) in adults with long COVID-19, identified through database and manual searches. The review itself had no comparison group and no meta-analysis. Included studies examined vitamin D, multinutrient/nutraceutical formulations, amino acids and metabolic support, creatine, oxaloacetate, nitric-oxide boosters, gut microbiota-targeted therapies, and diet/lifestyle programs; comparisons included placebo, controls, or another formulation. Examples reported: in 80 people with post-COVID-19 syndrome, weekly vitamin D improved fatigue (p = 0.024), anxiety (p = 0.011), and cognitive function (p = 0.012), with no effects on depression, sleep quality, or inflammatory markers. A single 200,000 IU vitamin D3 dose in 144 hospitalized patients showed no benefit on persistent symptoms or quality of life. Magnesium plus vitamin D improved depression (73.2% vs 34.5% remission, p = 0.006). PIRV-F20 in 44 long COVID-19 patients improved six-minute walking distance (+40 m vs +10 m, p = 0.02) but not strength or symptoms. Noni in 188 post-COVID-19 patients reduced fatigue (61.5% vs 24.3%), cognitive symptoms (59.4% vs 21.6%), and joint pain (66.2% vs 33.8%). SIM01 in 463 individuals alleviated core symptoms (all p < 0.01). Beetroot juice in 31 patients showed no significant between-group differences. Side effects and withdrawals were not reported in the recorded data. The authors state no formal quality appraisal was performed and causal inferences cannot be made.

  7. Interventions for Long COVID: A Narrative Review.2025 · review
    Summary

    This narrative review synthesized evidence from 97 studies (n=8260, 103 publications) on interventions for common long COVID symptoms: fatigue, neurocognitive symptoms, anxiety, depression, and sleep issues. The review included randomized and non-randomized studies and compared medications, rehabilitation, behavioral and mind-body programs, supplements, complementary treatments, and COVID-19 vaccination with placebo, usual care, no treatment, or other active comparators. For vortioxetine versus placebo, one RCT (n = 141) reported a significant reduction in depression symptoms (adjMD of −1.52; 95% CI −2.85 to −0.19) and improvement in quality of life (WHO-5, adjMD of 2.36; 95% CI 0.77 to 3.94), with mixed cognitive results. An RCT of “Fit after COVID” CBT (n=114) reported improvement in fatigue (CIS-fatigue: MD −8.8; 95% CI −11.9 to −5.8), cognitive impairment (CIS-concentration: MD −5.1; 95% CI −6.9 to −3.4), and physical function (SF-36-Physical Health: MD 7.1; 95% CI 2.9 to 11.3). Hyperbaric oxygen therapy (n=73) improved fatigue (SF-36 energy subscale, 18.2 vs 6.0, p=0.029) and sleep quality (PSQI, 8.1 vs 9.2, p=0.042) versus sham. Transcranial direct current stimulation (n=47) reduced physical fatigue (MFIS-Physical: p=0.034) but not overall fatigue (MFIS-Total: p=0.184). A COVID-19 vaccine study (n=453) found no statistically significant difference in fatigue, depression, or sleep quality. Adverse events included treatment-related reactions with vortioxetine (26.8% vs. 22.1%), non-serious adverse events with AXA1125 (RR 2.62, 95% CI 1.00 to 6.89), and similar adverse event rates with SIM01 (10% vs. 11%; p=0.63).

  8. Nutritional Interventions, Nutraceuticals, and Metabolic Therapies for Long COVID and Post-COVID-19 Vaccination Syndrome2025 · review
    Summary

    This REVIEW ARTICLE summarizes nutritional, nutraceutical, and metabolic treatments for long COVID/post-acute COVID-19 syndrome (PACS) and post-COVID-19 vaccination syndrome (PCVS); it reports no own cohort or setting. For low-dose naltrexone (LDN), O’Kelly et al. reported benefits in 52 long COVID patients over a 2–3-month period, including improvement in self-reported activities of daily living, energy, pain, concentration, sleep disturbance, and overall recovery, and decreased coughing, chest tightness, personality changes, low mood, and joint discomfort; pain improved most. In observational research by Glynne et al., 72% of individuals with long COVID who underwent antihistamine treatment showed noticeable but gradual symptom improvement, except dysautonomia. A nonrandomized controlled clinical experiment found 6 weeks of oral anhydrous enol-oxaloacetate (AEO) decreased physical and mental fatigue in ME/CFS and long COVID; ME/CFS patients receiving 500 and 1000 mg twice a day and three times a day improved from 21.7 to 33.3% versus baseline, and long-COVID fatigue improved up to 46.8% over baseline. A randomized controlled clinical trial reported vitamins K2/D3 improved GI and inflammatory markers, the RECOVER long COVID index, and other long COVID symptoms. Among 668 responders with long COVID, between 40 and 70% reported some symptom improvement after nattokinase, serrapeptase, or lumbrokinase; 13 out of 14 long COVID patients in a case series who fasted for an extended period improved. The review notes increased free zinc may negatively affect antibody production and excess zinc is harmful. The authors state additional large-scale controlled studies and future randomized controlled trials are needed.

  9. A Review Article on Exercise Intolerance in Long COVID: Unmasking the Causes and Optimizing Treatment Strategies.2023 · review
    Summary

    This critical review examined the possible causes and links among chronic fatigue, reduced physical activity, and exercise intolerance in patients with PASC/long COVID, with overlap discussed for ME/CFS. It reports no own participants, setting, enrolment, follow-up, or analysed sample. The review describes multiple therapeutic approaches rather than testing them in a new cohort. For redox-based supplementation, it reports a non-randomized clinical trial by Cash et al of anhydrous enol oxaloacetate capsules in ME/CFS patients and patients with chronic fatigue after SARS-CoV-2 infection, with improvements in fatigue from baseline after adding 500 and 1000 mg over 6 weeks. It also states that regular 14-day inhalation of molecular hydrogen positively affects physical and respiratory functions in patients with SARS-CoV-2 infection. The authors conclude that a gradual return to physical activity can reduce inflammatory markers, encourage overall fitness, and reduce fatigue; that meditation is an effective concomitant treatment for post-viral ME/CFS symptoms; and that HBOT has beneficial effects including reduced fatigue and pain. They also note that CBT did not lead to objective improvements in physical performance or restore ability to work. Harms statements include that relapses in ME/CFS patients can be partially induced by excessive exercise, and that traditional CONC programs can worsen dyspnea and increase oxidative stress. The authors state further research is needed and that more sham-controlled studies are needed for PEMF.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime